Stephenson Cancer Center

Summary

Stephenson Cancer Center is a medical facility located in Oklahoma City, Oklahoma. This center is recognized for care of Solid Tumors, Cancer, Ovarian Cancer, Pancreatic Cancer, Lung Cancer and other specialties. Stephenson Cancer Center is involved with conducting 295 clinical trials across 305 conditions. There are 31 research doctors associated with this hospital, such as Rene Y. McNall-Knapp, Debra L. Richardson, Kathleen Moore, M.D., MS, and Raid Aljumaily.

Top PIs

Clinical Trials running at Stephenson Cancer Center

Ovarian Cancer

Endometrial Cancer

Pancreatic Cancer

Cancer

Solid Tumors

Breast Cancer

Lung Cancer

Colorectal Cancer

Acute Myeloid Leukemia

Bladder Cancer

Mirvetuximab + Bevacizumab

for Ovarian Cancer

GLORIOSA is a Phase 3 multicenter, open label study designed to evaluate the safety and efficacy of mirvetuximab Soravtansine + Bevacizumab as maintenance therapy in participants with platinum-sensitive ovarian, primary peritoneal or fallopian tube cancers with high folate receptor-alpha (FRα) expression.

Recruiting

2 awards

Phase 3

Avutometinib + Defactinib

for Ovarian and Cervical Cancer

The purpose of this research is to test the effectiveness and safety of the study drugs (VS-6766 and defactinib), and see what effects (good and bad) these drugs have on the patients with endometrioid cancer, mucinous ovarian cancer, high-grade serous ovarian cancer, or solid gynecological cancer.

Recruiting

1 award

Phase 2

10 criteria

REGN4018 + Cemiplimab

for Ovarian Cancer

The main purpose of this study is to: * Learn about the safety of ubamatamab and to find out what dose of ubamatamab can be given alone or with cemiplimab to patients with ovarian cancer or cancer of the uterus * The study will also look at the levels of ubamatamab and/or cemiplimab in the body and measure how well the body can remove the study drug(s). This is called pharmacokinetics * The study will also look at any signs that ubamatamab alone or with cemiplimab can treat recurrent advanced ovarian cancer or cancer of the uterus * To find out how safe and tolerable pretreatment is in combination with ubamatamab and to see how well it works to prevent or minimize Cytokine Release Syndrome (CRS)

Recruiting

1 award

Phase 1 & 2

8 criteria